<DOC>
	<DOC>NCT00702702</DOC>
	<brief_summary>Eligible female subjects will be randomly assigned to one of the three treatment groups. Subjects will receive 325 mg (65 mg elemental iron) iron supplements to be taken twice daily during study drug treatment. The study duration is approximately six months, which is comprised of a 4 - 6 week screening period, a three-month drug treatment period, and a one-month follow-up period.</brief_summary>
	<brief_title>Safety and Efficacy of Proellex in Pre-menopausal Anemic Women With Symptomatic Uterine Fibroids</brief_title>
	<detailed_description>Eligible female subjects will be randomly assigned to one of the three treatment groups. Subjects will receive 325 mg (65 mg elemental iron) iron supplements to be taken twice daily during study drug treatment. The study duration is approximately six months, which is comprised of a 4 - 6 week screening period, a three-month drug treatment period, and a one-month follow-up period. Study was terminated by clinical hold.</detailed_description>
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<criteria>Female, between the ages of 18 and 48 years with Body Mass Index (BMI) between 18 and 39, inclusive; Anemic, defined as hemoglobin levels less than or equal to 10.5 g/dL and uterine fibroidassociated symptoms indicated by a history of excessive menstrual bleeding; Surgical interventions for uterine fibroids (e.g. hysterectomy or myomectomy) planned or anticipated after the study; Willing to comply with all study procedures, including the endometrial biopsies and blood draws for all visits, including Followup Visits Postmenopausal women or women likely to become postmenopausal during the study, defined as one or more of the following: Six months or more (immediately prior to Screening Visit) without a menstrual period, or Prior hysterectomy, or Prior bilateral oophorectomy (unilateral oophorectomy is not exclusionary if regular menstruation is occurring); Females who have undergone a uterine arterial embolization, or endometrial ablation therapy (previous myomectomy is acceptable) for any cause; Documented endometriosis or active pelvic inflammatory disease (PID); Having a diagnosis, or suspected diagnosis, of carcinoma of the breast or reproductive organs; Known active infection with HIV, Hepatitis A, B or C, Gonorrhea, or Chlamydia; Use of prohibited concomitant medications: 1. DepoProvera use must cease ten months prior to first dose of study drug, or 2. GnRH agonists use (e.g. Lupron Depot) must cease six months prior to first dose of study drug, or 3. Oral contraceptive or other hormonal treatments use must cease for 30 days prior to the start of the study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Uterine fibroids</keyword>
	<keyword>Anemia</keyword>
</DOC>